Abstract
Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Current Pharmaceutical Biotechnology
Title: Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents
Volume: 1 Issue: 3
Author(s): S. D. Nuttall, R. A. Iring and P. J. Hudson
Affiliation:
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Abstract: Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Export Options
About this article
Cite this article as:
Nuttall D. S., Iring A. R. and Hudson J. P., Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents, Current Pharmaceutical Biotechnology 2000; 1 (3) . https://dx.doi.org/10.2174/1389201003378906
DOI https://dx.doi.org/10.2174/1389201003378906 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Terpenoids form the Sea: Chemical Diversity and Bioactivity
Current Organic Chemistry Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics CIITA and the MHCII Enhanceosome in the Regulation of MHCII Expression
Current Genomics Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Subcellular Trafficking in Rhabdovirus Infection and Immune Evasion: A Novel Target for Therapeutics
Infectious Disorders - Drug Targets TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Transcriptional and Post-Transcriptional Regulations of Junction Proteins in Mammalian estes – Implications on Male Contraceptive Development
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Yin and Yang of CD4+ Regulatory T Cells in Autoimmunity and Cancer
Current Medicinal Chemistry Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Epithelial-Mesenchymal Transitions and Cancer
Current Genomics Bioactive Natural Products from the Antarctic and Arctic Organisms
Mini-Reviews in Medicinal Chemistry Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Known Triterpenes and their Derivatives as Scaffolds for the Development of New Therapeutic Agents for Cancer
Current Medicinal Chemistry Topoisomerases and Tubulin Inhibitors: A Promising Combination for Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents